-
The Targeted Pulse: CAR T Label Updates, FDA Approvals, and More
06 Jul 2025 11:27 GMT
… development this week saw the FDA approve updated labels for chimeric … rituximab (Rituxan) for relapsed follicular lymphoma. This groundbreaking, chemotherapy-free treatment option … for oncologists here.
Beyond new drug approvals, this week also highlighted …
-
Oncology Drugs Approved by the FDA in June
02 Jul 2025 14:27 GMT
… orchiectomy.1
Treatment with darolutamide … multicenter, single-arm trials.3
TRUST-I … Revlimid) and rituximab (Rituxan) for adult patients … ;/www.fda.gov/drugs/;resources-information-approved-drugs/fda-approves-tafasitamab-cxix-relapsed-or …
-
Therapies Which Received FDA Approval in July: What Patients Should Know
01 Jul 2025 18:12 GMT
… Food and Drug Administration (FDA) approved multiple cancer treatments and combination … oncologist at Weill Cornell Medicine and NewYork-Presbyterian, … with Revlimid (lenalidomide) and Rituxan (rituximab) for adults … two open-label clinical trials, TRUST-I and …
-
OncLive’s FDA Approval Report: The Regulatory Rundown for June 2025
01 Jul 2025 21:03 GMT
… of Medicine, said in a recent interview. “The drug has … 3, single-arm ENVISION trial (NCT05243550), in which patients … (Revlimid) and rituximab (Rituxan) for adult patients with … TROPION trials and the implications for the NSCLC treatment landscape. …
-
Oncologists’ Guide to the FDA Approval of Tafasitamab for Relapsed FL
27 Jun 2025 16:32 GMT
… (Revlimid) and rituximab (Rituxan) for relapsed/refractory … MD, hematologist/medical oncologist at Rocky Mountain … patients outside of clinical trials.
Tafasitamab, a humanized … lymphoma treatment. Poh reflected on the broader implications, stating, …
-
CAR T Transforms Treatment Landscape for Blood Cancers
27 Jun 2025 16:12 GMT
… participated in the original trials and many that led to … and qualified for a trial we were running at … therapy that combined immunotherapy, [Rituxan], with a small molecule. … attend informational classes, understand the treatment process, and be prepared …
-
Dr Danilov on the Evolution of Chemotherapy-Free Treatment Options in MCL
27 Jun 2025 19:59 GMT
… Early Clinical Therapeutics, medical director of the … and chronic lymphocytic leukemia treatment paradigms.
The emergence … comparator in this trial included rituximab (Rituxan), cyclophosphamide, doxorubicin, … randomized phase 3 trials and smaller phase …
-
Mosunetuxumab/Polatuzmab Vedotin Combo Advances R/R LBCL Treatment Options
27 Jun 2025 00:29 GMT
… ORR) compared with rituximab (Rituxan), gemcitabine, and oxaliplatin ( … antibody mosunetuzumab and antibody-drug conjugate (ADC) … nonchemotherapeutic option in the treatment landscape. Submissions of … authorities, including the FDA, are anticipated.1
…
-
Novel Targeted, Chemo-Free, and Cellular Therapies Are Poised to Transform Treatment Paradigms in B-Cell Malignancies
25 Jun 2025 14:47 GMT
… of Early Clinical Therapeutics, medical director of the Early … to R-CHOP [rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, … including] smaller phase 2 [trials] as well as randomized phase … for the treatment of CLL.
How has the FDA approval …
-
Q3 2025: 10 FDA Decisions to Watch in the Realm of Oncology
24 Jun 2025 21:08 GMT
… events and few treatment discontinuations.
Sunvozertinib … compared with rituximab (Rituxan) plus GemOx (n = … trial (NCT03416530), and 3 phase 2 trials (NCT03295396; NCT02525692; NCT03134131), the drug … 2025, Foresee Pharmaceuticals announced the FDA issued a …